… For the direct thrombin inhibitor dabigatran etexilate, a calibrated diluted thrombin time or …
For dabigatran, this is the inhibition of thrombin formation and for anti–factor Xa drugs, the …

… on the pharmacokinetics and pharmacodynamics of DOACs and of strategies proposed to
adjust doses according to the level of renal dysfunction. The pharmacokinetic characteristics …

… the pharmacokinetics of dabigatran (factor IIa/thrombin inhibitor) and apixaban, edoxaban
and rivaroxaban (factor Xa) inhibitors. … The oral bioavailability of dabigatran etexilate is low, at …

… The DOACs, dabigatran (a reversible direct thrombin inhibitor) and the … Dabigatran can
be orally administered as the prodrug, dabigatran etexilate which differs from dabigatran by an …

… 2.3 Dabigatran The thrombin inhibitor dabigatran is administered as a prodrug (dabigatran
etexilate) because active dabigatran is a poorly available hydrophilic zwitterion [3]. Other …

… thrombin inhibitor. The amidine group of … study, the pharmacokinetics and safety profile of
dabigatran in healthy … ) and 150 mg bid—adopted for the registration of dabigatran etexilate. …

… direct thrombin inhibitor activity for dabigatran. Studies were excluded if they concerned
review papers, meta-analyses, case reports or series, non-English articles, poster presentations, …

… This review aims to application of Dabigatran etexilate in … and disposition of the oral direct
thrombin inhibitor, dabigatran, in … , pharmacokinetics, and pharmacodynamics of dabigatran …

… inhibitor of P-glycoprotein and a moderate inhibitor of CYP3A4 [35]. As expected, dronedarone
increases C max and AUC of dabigatran etexilate … Dronedarone doubles dabigatran AUC …

… The thrombin inhibitor dabigatran is administered as the prodrug dabigatran etexilate,
which is a substrate of esterases and P-glycoprotein (P-gp). Dabigatran is eliminated via renal …